Prices delayed by at least 15 minutes | Print
Faron Pharmaceuticals Oy (FARN)
ORD NPV (DI)Open
30.00p
Previous close
30.00p
Trade high
30.60p
Volume
19,456
Year high
103.458p
Year low
22.2056p
Dividend yield
–
Market capitalisation
£57.52 mn
P/E ratio
–
ISIN
FI4000153309
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment
Share price
Company profile
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
News
Recent trades
| Date | Time | Price | Quantity | Value (£) |
|---|---|---|---|---|
| 12/11/2026 | 11:23:50 | 28.35 | 14,134 | 4,006.99 |
| 12/11/2026 | 10:29:07 | 30.45 | 3,284 | 999.98 |
| 12/11/2026 | 09:02:22 | 30.6 | 310 | 94.86 |
| 12/11/2026 | 08:25:55 | 28.35 | 1,728 | 489.89 |
| 11/11/2026 | 04:26:27 | 33 | 5 | 1.74 |